



HHS Public Access

Author manuscript

Nat Commun. Author manuscript; available in PMC 2014 June 16.

Published in final edited form as:

Nat Commun. 2013 ; 4: 2823. doi:10.1038/ncomms3823.

Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology

Ingmar Mederacke¹, Christine C. Hsu^{#1}, Juliane S. Troeger^{#1}, Peter Huebener¹, Xueru Mu¹, Dianne H. Dapito², Jean-Philippe Pradere¹, and Robert F. Schwabe^{1,2}

¹ Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA

² Institute of Human Nutrition, Columbia University, New York, NY 10032, USA

These authors contributed equally to this work.

Abstract

Although organ fibrosis causes significant morbidity and mortality in chronic diseases, the lack of detailed knowledge about specific cellular contributors mediating fibrogenesis hampers the design of effective anti-fibrotic therapies. Different cellular sources including tissue-resident and bone marrow-derived fibroblasts, pericytes and epithelial cells have been suggested to give rise to myofibroblasts, but their relative contributions remain controversial, with profound differences between organs and different diseases. Here we employ a novel Cre-transgenic mouse that marks 99% of hepatic stellate cells (HSCs), a liver-specific pericyte population, to demonstrate that HSCs give rise to 82-96% of myofibroblasts in models of toxic, cholestatic and fatty liver disease. Moreover, we exclude that HSCs function as facultative epithelial progenitor cells in the injured liver. On the basis of these findings, HSCs should be considered the primary cellular target for anti-fibrotic therapies across all types of liver disease.

Introduction

Fibrotic diseases account for up to 45% of deaths in developed countries, but we still lack effective anti-fibrotic therapies¹. Knowledge about cells contributing to the myofibroblast pool and extracellular matrix (ECM) production in organ fibrosis is important for designing targeted therapies^{2,3}. Several cell populations including tissue-resident or bone marrow-derived fibroblasts, pericytes and epithelial cells have been suggested as relevant

Users may view, print, copy, download and text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence: Robert F. Schwabe; Department of Medicine, Columbia University, College of Physicians & Surgeons, Russ Berrie Pavilion, Room 415, 1150 St. Nicholas Ave, New York, NY 10032; rfs2102@cumc.columbia.edu; Tel: (212) 851-5462, Fax: (212) 851-5461.

Author contributions: I.M. performed *in vivo* injury models, primary cell isolations, generation of double, triple and quadruple transgenic mice, data acquisition, data analysis and drafted the manuscript. C.C.H. performed immunohistochemistry and data analysis. J.S.T. generated LratCre transgenic mice. P.H. isolated primary hepatocytes. X.M. performed immunohistochemistry. D.H.D. performed immunohistochemistry and cell isolations. J.P. performed bone marrow transplantations and macrophage isolations. R.F.S. designed and oversaw the study, performed data analysis and drafted the manuscript.

Conflict of interest

The authors declare no conflict of interest.

contributors to the myofibroblast pool^{2,3} but their contribution varies between organs and different diseases, and remains a matter of debate.

Liver fibrosis occurs as a result of chronic liver disease and is associated with severe morbidity and mortality⁴. Hepatic stellate cells (HSCs), a pericyte-like cell population of the liver, and portal fibroblasts are widely considered the most relevant sources of hepatic myofibroblasts, but their precise contribution remains unknown. It is thought that the underlying liver disease determines the cell types that contribute to the myofibroblast pool, with profound differences between toxic and cholestatic liver diseases, and portal fibroblast exerting a key role in the latter⁴⁻⁷. Other cell types such as bone marrow-derived fibrocytes may also contribute to the myofibroblast pool, but to a lesser degree^{8,9}. However, most evidence about relevant myofibroblast sources and functions derives from cell isolates and *in vitro* studies¹⁰⁻¹², whereas *in vivo* studies quantifying the relative contribution of different cell populations in the fibrotic liver are missing. In this regard, fate-tracing studies have excluded a contribution of hepatocytes and cholangiocytes to the myofibroblast pool¹³⁻¹⁵, but positive identification of cell types contributing to the myofibroblast pool by fate-tracing is lacking. As such, previous studies employing collagen-driven Cre or Wt1-Cre have tracked either all collagen-producing myofibroblasts but not specific cellular sources of myofibroblasts¹²; or mesothelial cells, which give rise to subcapsular fibroblasts within 150 μm of the liver surface but not to intrahepatic myofibroblasts, i.e. those that cause organ fibrosis and its deleterious complications¹⁶. Attempts at fate-tracing HSCs, one of the prime candidates^{4,11,17}, using Cre driven by the human glial fibrillary acidic protein promoter (hGFAPCre) are hampered by the fact that hGFAPCre marks cholangiocytes^{18,19} (<https://ndp.jax.org/NDPServe.dll?ViewItem?ItemID=1741&XPos=11536496&YPos=5169511&ZPos=0&Lens=1.25&SignIn=Sign%20in%20as%20Guest>), thereby limiting interpretation.

Here we employ a novel fate tracing method for HSCs to demonstrate that HSCs are the dominant contributors to collagen-producing myofibroblasts in models of toxic, biliary and fatty liver fibrosis. Moreover, we exclude that HSCs serve as facultative epithelial progenitors in the injured liver.

Results

LratCre but not hGFAPCre labels HSCs

Using three different Cre reporters, we confirmed that hGFAPCre mice labeled bile ducts and cytokeratin 19-expressing cholangiocytes (Fig. 1A, E-H). Of note, hGFAPCre mice did not efficiently mark HSCs or collagen-producing myofibroblasts (Fig. 1B-G). Likewise, mice expressing Cre under the murine *Gfap* promoter did not label HSCs (Fig. 1I). To achieve faithful labeling of HSCs, we generated a bacterial artificial chromosome (BAC) transgenic mouse in which Cre expression is driven by lecithin-retinol acyltransferase (*Lrat*) (Supplementary Fig. S1B). *Lrat* was selected in screens among several candidates because of high expression in HSCs, virtually undetectable expression in hepatocytes, Kupffer cells and cholangiocytes (Fig. 2A), and its key role in the formation of retinyl ester-containing lipid droplets, one of the defining features of HSCs²⁰. In contrast to a previous study²¹, we also did not detect *Lrat* protein or mRNA expression in endothelial cells (Fig. 2A,

Supplementary Fig. S1A). LratCre-transgenic mice marked 99% of HSCs as demonstrated by flow-cytometry and immunohistochemistry in two different Cre reporter mice, showing nearly complete overlap of HSC markers desmin and Pdgfr β with LratCre-induced ZsGreen Cre reporter by confocal microscopy, no significant overlap with hepatocyte, macrophage, and cholangiocyte markers and only few spots of overlap with endothelial cell markers, most likely due to their very close proximity to HSCs (Fig.2B-E, Supplementary Fig. S1C-G).

HSCs are the main contributors to toxic liver fibrosis

To determine the contribution of HSCs to the myofibroblast pool, we first subjected LratCre mice to the well-established model of carbon tetrachloride (CCl₄)-induced liver fibrosis. In this model, LratCre-induced ZsGreen expression -marking HSCs- and α SMA expression -marking myofibroblasts- completely overlapped, and displayed micro- and macroscopic ZsGreen fluorescence with the characteristic septal pattern of liver fibrosis (Fig.3A-B). To determine the relative contribution of HSCs to the myofibroblast pool, we quantified the overlap between LratCre-induced Cre reporter and α SMA. In CCl₄-induced liver fibrosis, the overlap between LratCre-induced ZsGreen and α SMA was 93.6% (\pm 2.3% SD, n=4, Fig. 3B), providing evidence that HSCs are the almost exclusive source of myofibroblasts in toxic liver fibrosis. To confirm this data by a second approach, we generated LratCre mice co-expressing red-fluorescent Cre reporter tdTomato and a green-fluorescent Col-GFP reporter, which faithfully marks collagen-producing cells²². LratCre-induced tdTomato almost completely overlapped with Col-GFP fluorescence in the CCl₄ model (96.0% \pm 2.4%SD, n=4, Fig.3B), thus matching the degree of overlap that we found between α SMA and LratCre-induced ZsGreen. Accordingly, nearly all α SMA-positive cells were also Col-GFP-positive (Fig.3C). To exclude that our data may be specific to the CCl₄ model, we confirmed our findings in a second well-established model of toxic liver fibrosis, induced by thioacetamide (TAA) treatment. Livers from TAA-induced treated mice also displayed a characteristic macro- and microscopic septal pattern of ZsGreen fluorescence, and the same range of co-localization between LratCre-induced TdTomato and Col-GFP fluorescence (94.8% \pm 0.3%SD, n=3) as in the CCl₄ model (Supplementary Fig.S2A-C). To further substantiate the functional contribution of HSCs to fibrogenesis, we ablated HSCs via LratCre-induced diphtheria toxin receptor. This strategy strongly reduced HSC numbers in untreated and CCl₄-treated livers, albeit not completely (Fig.3D-E, Supplementary Fig. S3A). However, it should be noted that this approach typically does not result in complete ablation unless a strongly intensified regimen of diphtheria toxin injection is employed²³. The reduction of α SMA and profibrogenic gene expression by at least the same degree as ablation of HSCs, assessed by desmin mRNA and immunohistochemistry (Fig.3D-E), confirms the relevant contribution of HSCs to fibrogenesis. In contrast, hepatic inflammation, injury and expression of endothelial marker *vWf* were not affected by HSC ablation (Supplementary Fig. S3B-D).

HSCs are the main contributors to biliary liver fibrosis

After having established HSCs as main contributors to toxic liver fibrosis, we next determined the contribution of HSCs to cholestasis-induced liver fibrosis. In this setting, portal fibroblasts are believed to be an essential contributor to fibrogenesis^{4,5,7}. In three

well-established models of cholestasis-induced liver fibrosis, bile duct ligation (BDL), 3,5-diethoxycarbonyl-1,4-dihydro-collidin (DDC)-containing diet, and *Mdr2*^{ko} mice, tdTomato expression almost completely overlapped with Col-GFP reporter expression, reaching >89% co-localization and thus almost the same degree as in toxic liver fibrosis (Fig.4A-C,E). This data was confirmed by flow-cytometric analysis of the entire non-parenchymal cell pool, in which 82-85% of collagen-producing cells were tdTomato-positive HSCs (Fig.4D-E). A high contribution of HSCs to collagen-producing cells was even noted during early cholestatic liver fibrosis (87-90% co-localization, Supplementary Fig.S4A-D, G), and in the methionine-choline-deficient diet model of non-alcoholic steatohepatitis disease (Supplementary Fig.S4E-F). Similar to the CCl₄-induced fibrosis, LratCre not only marked collagen-producing cells but also α SMA-expressing cells, with 80% and 88% overlap between α SMA and LratCre-induced tdTomato after 7d and 14d BDL, respectively, and a strong overlap between α SMA-positive and Col-GFP-positive cells (Supplementary Fig.S5A-B).

Lrat-negative portal fibroblasts-like cells are distinct from HSCs

In addition to LratCre-labeled, Col-GFP-positive HSCs, we also found a small population of Col-GFP-positive but LratCre-unlabeled fibroblasts, both in the liver and in cell isolates of cholestatic fibrosis models. These cells were predominantly located around the portal tracts, and did not contain retinoid lipid droplets, consistent with characteristics of portal fibroblasts (Fig. 4F, H). This LratCre-negative, Col-GFP-positive population of portal fibroblast-like cells (PLFC) showed low expression of genes characteristic for HSCs, such as *Lrat*, *Lhx2* and *HGF*, and was morphologically distinct from HSCs (Fig.4G-H). PLFC were α SMA- and Col-GFP positive, and abundantly expressed *Acta2*, *Colla1*, *Lox*, *Timp1* and *Vim* in comparison to whole liver (Supplementary Fig.S6A-B), confirming them as myofibroblasts. However, they expressed significantly lower levels of fibrogenic genes than HSCs in our isolates (Fig.4G), thus excluding that PLFC might represent a less abundant, but more fibrogenic population than HSCs. Together, these data indicate that portal fibroblast constitute a myofibroblast population that is not HSC-derived and significantly less abundant than HSCs, and likely fulfils specialized functions in cholestatic liver disease.

Myofibroblasts derive from LratCre-labelled retinoid-positive HSCs

α SMA staining in normal liver (where HSCs are quiescent and do not express α SMA) revealed that LratCre also labeled some vascular smooth muscle cells (VSMCs, Supplementary Fig. S7A). This may be explained by the fact that VSMCs and pericytes/HSCs are considered to be of the same lineage²⁴, sharing a common precursor in the liver²⁵. Although LratCre-labeled HSCs outnumbered LratCre-labeled VSMCs by a factor of >200 (Supplementary Fig. S7B), we wanted to further exclude a major contribution of LratCre-labeled VSMCs, or any other non-HSC population to the hepatic collagen-producing fibroblast pool. As specific labeling of hepatic VSMCs is not feasible, we employed retinoid fluorescence to identify LratCre-labeled myofibroblasts of HSC origin. Retinoid fluorescence was observed in >90% of tdTomato- and Col-GFP-positive cells in the CCl₄, BDL and *Mdr2*^{ko} fibrosis models (Supplementary Fig. S7C-D), albeit at a lower level than in quiescent HSCs, thus confirming that these myofibroblasts are of HSC and not of VSMC

origin. Collectively, our data establish HSCs as principal contributors to the collagen-producing myofibroblast pool across all types of liver fibrosis.

HSCs are not epithelial progenitors

Next, we determined whether HSCs may exert functions besides fibrogenesis in liver injury. Previous studies, employing hGFAP-Cre and α SMA-CreERT2 mice for fate-tracing, suggested that up to 24% of hepatocytes were derived from HSCs in the methionine-choline-deficient ethionine-supplemented (MCDE) diet and BDL models^{18,19}. Employing LratCre mice, we tested whether short- and long-term injury induced by BDL, Mdr2^{ko}, MCDE diet, DDC diet, CCl₄, TAA or 70% partial hepatectomy resulted in the generation of HNF4 α -positive hepatocytes expressing ZsGreen Cre reporter, thus identifying them as progeny of LratCre-expressing HSCs. Although we found rare HNF4 α -positive hepatocytes (at a frequency of \approx 0.2 per 1,000 cells) expressing Cre reporter ZsGreen, none of the injury models increased this rate in the liver (Fig.5A-G, Supplementary Fig. S8A-C). We also did not observe increased ZsGreen-positive cells with hepatocyte morphology (positive control shown in the insert of Fig.5A) in liver sections (Fig.5a-f, and Supplementary Fig.8B-C), or in primary hepatocyte isolates (Fig.5HI, Supplementary Fig. S8D). Furthermore, LratCre-marked cells did not give rise to cytokeratin-positive liver progenitor cells or cholangiocytes in any of the chronic injury models (Fig.2E, Supplementary Fig. S9A-E). Collectively, these data exclude that HSCs function as epithelial progenitors.

LratCre-positive HSCs are not bone marrow-derived

Finally, we employed Lrat-Cre mice to assess whether HSCs constitute a liver-resident or bone marrow-derived cell population, a point of substantial controversy²⁶⁻²⁸. We did not detect LratCre-labeled HSCs in normal liver or fibrotic livers after BDL or long-term injury induced by 20 CCl₄ injections despite successful BM transplantation as evidenced by mTom-positive (i.e. non-recombined) BM-derived cells in the spleen and mTom- and F4/80-double-positive BM-derived macrophages in the liver (Fig. 6A-C). These data confirm HSCs as liver-resident cell population.

Discussion

Despite the lack of solid *in vivo* evidence that HSCs are the primary drivers of liver fibrosis, much of the current research and drug discovery work focus on this cell type. After the discovery that HSCs produce significantly larger amounts of collagen than hepatocytes and endothelial cells *in vitro* and thus constitute a prime candidate for hepatic myofibroblast precursors¹¹, little progress has been made to further establish and precisely quantify the relative contribution of HSCs to the hepatic myofibroblast pool and liver fibrosis *in vivo*. Most subsequent studies have investigated HSC activation in cell cultures, a process that differs substantially from *in vivo* activation^{10,29}, or studied HSC isolates from normal and fibrotic livers^{10,12}. Because of the lack of fate tracing techniques that specifically label precursor populations such as HSCs, sources of hepatic myofibroblasts have not yet been established or precisely quantified *in vivo*. Fate-tracing has excluded a contribution for epithelial cells to the hepatic myofibroblast pool¹³⁻¹⁵, and characterized the embryonic origin of HSCs¹⁶. However, positive identification of myofibroblast precursors has not been

achieved as fate-tracing approaches have either labeled all myofibroblast populations but not specific precursors¹³, or subpopulations such as subcapsular fibroblasts that contribute little to organ fibrosis and the deleterious complications of fibrosis due to their sparsity and anatomic location¹⁶.

The most important finding of our study is the *in vivo* identification of HSCs as a universal and liver-resident source for myofibroblasts, exerting a dominant role across toxic, biliary and fatty liver diseases. These data suggest that HSCs should be considered the primary target for the development of new anti-fibrotic therapies, which has become an important focus of the field³⁰⁻³². Revealing HSCs as the by far dominant source in cholestatic fibrosis is unexpected as portal fibroblasts have been considered a key contributor in cholestatic liver fibrosis^{4,5,7}. The consistently high contribution of HSCs was observed in three different models of cholestasis, including the Mdr2ko model, which mimicks defects in cholestatic patients³³. Thus, our data refute the hypothesis that the underlying disease dictates the cell type that contributes to the myofibroblast pool in liver fibrosis, and instead establish HSCs as universal responders that trigger wound repair across different types of liver injury. Despite the dominant role of HSCs, there was a higher contribution of non-HSC myofibroblast sources in biliary than in toxic liver fibrosis. Accordingly, we identified a population of LratCre-negative fibroblasts around portal tracts that were distinct from HSCs in terms of gene expression and anatomic localization. Despite being less abundant than HSCs, these cells most likely exert important functions in cholestatic liver disease. While portal fibroblasts probably do not make a major contribution to organ fibrosis and associated complications such as portal hypertension due to their low abundance, their anatomic localization suggests that they may exert specialized functions related to bile ducts. This might be the mechanical stabilization of bile ducts as an adaptive response to increased pressure, or a contribution to biliary stenosis as a maladaptive response. It is also conceivable that portal fibroblasts represent a cell population that has a role in early biliary fibrosis serving as “rapid responders”⁷, and that is essential in recruiting HSCs, which then in turn contribute to the majority of ECM production. Further studies should also determine whether LratCre-negative portal fibroblasts may produce different type of ECM than HSCs.

The second relevant finding of our study is that HSCs are not progenitor cells, and do not contribute to the generation of hepatocytes in the injured liver. Previous studies had suggested that HSCs contribute up to 24% of newly formed hepatocytes^{18,19}. As we labelled 99% of HSCs by LratCre and investigated their contribution to hepatocyte generation in liver sections from seven different injury models and in primary hepatocyte isolates from two injury models, in the liver and in hepatocyte isolates without finding increased number of HNF4a- and ZsGreen-double positive cells, or ZsGreen-positive cells with hepatocyte shape, we can exclude HSCs as a source for epithelial regeneration in the liver. Our findings are congruent with studies showing that hepatocytes and to a lesser degree, bipotential progenitors functions as efficient cellular sources for epithelial regeneration³⁴⁻³⁶.

Finally, our data, showing that GFAPCre transgenic mice efficiently label cholangiocytes but not a significant amount of HSCs, suggests that previous studies employing GFAPCre^{13,18,19,37,38} are likely not HSC-specific. We cannot completely rule out that there

may be differences in the recombination in different floxed alleles or Cre reporters, but have tested three Cre reporters, confirmed GFAPCre by sequencing, tested functional Cre expression in brain sections, and have used mice expressing Cre under the human GFAP as well as the murine Gfap promoter. Furthermore, previous publications^{18,19} and Jackson Laboratories (<https://ndp.jax.org/NDPServe.dll?ViewItem?ItemID=1741&XPos=11536496&YPos=5169511&ZPos=0&Lens=1.25&SignIn=Sign%20in%20as%20Guest>) have reported Cre activity in cholangiocytes.

Our study has several limitations. First of all, murine fibrogenesis may not fully reflect human fibrogenesis due to its shorter duration, different biology, and difficulties to model all relevant diseases adequately in mice. We have assessed the HSC contribution in a large number of murine models, but human confirmation is warranted. This may be achieved by developing markers that clearly distinguish between HSC and non-HSC myofibroblast populations such as portal fibroblasts. Second of all, LratCre also labeled some VSMCs in our study. This is likely due to the fact that pericytes and VSMCs share a common precursor in many organs, including the liver^{24,25}. However, we found that more than 90% of LratCre-labeled myofibroblasts contained retinoid lipid droplets characteristic for HSCs, thus providing strong evidence that LratCre-labeled myofibroblasts are indeed derived from HSCs. Third, it is conceivable that LratCre activity is turned on in non-HSC populations during fibrogenesis, and that we overestimate the contribution of HSCs. However, we found that non-HSC myofibroblast populations such as PLFC were LratCre-negative and distinct from HSC. We also did not find a significant amount of LratCre-labeled hepatocytes, cholangiocytes, endothelial cells or Kupffer cells in CCl₄-induced liver injury, providing further evidence that LratCre activity is not significantly induced in non-HSC populations in the injured liver. Moreover, the above-discussed finding that more than 90% of LratCre-positive myofibroblasts also contained retinoids characteristic for HSCs also excludes a significant contribution of non-HSC populations. As such, retinoid lipid droplets are a defining feature of HSCs and the only parameter by which they could be clearly defined to date. Tamoxifen-inducible LratCre would be helpful to further confirm these data and further exclude LratCre activity in other cell types during disease, but is likely to achieve a lower labeling efficacy than constitutive LratCre, and a less precise quantification of HSC contribution to the hepatic myofibroblast pool. Fourth, our isolation of PFLCs may contain cells other than portal fibroblasts as the employed isolation method relied on exclusion of HSCs and not on positive identification. Further establishment of high purity portal fibroblast isolates will allow more powerful qualitative comparison between HSCs and portal fibroblasts.

In contrast to the dominant role of HSCs in liver fibrosis, the contribution of pericytes in fibrosis of other organs remains controversial with some studies in kidney, lung and spinal cord³⁹⁻⁴¹ showing a key contribution but other studies reporting opposite findings^{42,43}. Confirming a key role for pericytes in fibrogenesis in additional organs may allow to determine common targets for anti-fibrotic therapies across different organs.

Methods

Generation of LratCre mice

A Cre-containing cassette was PCR-amplified with 60-bp overhangs homologous to the upstream and downstream sequence surrounding ATG site of the mouse Lrat gene. The PCR product was inserted into a BAC containing the mouse Lrat gene by recombineering. After removal of the Neo cassette by arabinose-induced flippase, BAC DNA was microinjected into the pronucleus of fertilized CBAXC57BL/6J oocytes. Out of six positive founders, the one showing the strongest LratCre-induced Cre reporter expression in liver and HSCs was used for further studies. Pups were born in a male/female ratio of 1:1 (50.3% vs 49.7%, n=179).

Mice and genotyping

Mice in which Cre expression is driven by the human GFAP promoter (hGFAPCre)⁴⁴, the murine Gfap promoter (mGfapCre)⁴⁵ and mice expressing Cre reporters ZsGreen, TdTomato⁴⁶ or mTom/mGFP⁴⁷ were obtained from Jackson. Mdr2ko mice⁴⁸ in FVB/N background have been described. For all experiments, LratCre mice were maintained in a mixed background after breeding 1-2 times into the ZsGreen, tdTomato reporter, mTom/mGFP strains of the C57Bl/6 background, or Mdr2ko mice. Mice for HSC isolations were used at ages 12-18 weeks. Mice used for fibrosis or injury models, or for non-parenchymal cell isolation were used at ages 8-12 weeks unless otherwise indicated. Mice of both genders were used with the exception of the BDL and DDC models for which only male mice were employed. Genotyping for LratCre was done using forward primer 5'- CCTTTCTTTGACCCCTGCAC and reverse primer 5'- GACCGGCAAACGGACAGAAG. Genotyping for hGFAPCre mice was done using forward primer 5'- ACTCCTTCATAAAGCCCT and reverse primer 5'- CGCCGCATAACCAGTGAAAC. The PCR product for hGFAPCre genotyping was sequenced and presence of human GFAP promoter sequence was confirmed.

Liver fibrosis and injury models

Toxic liver fibrosis was induced by intraperitoneal injections of either CCl₄ (0.5 μL/g, dissolved in corn oil at a ratio of 1:3) for various intervals, or of thioacetamide (dissolved in NaCl 0.9%) for 6 weeks (3 injections per week) at increasing concentrations (first dose: 50 mg/kg, second dose: 100 mg/kg, third to sixth dose: 200 mg/kg, all following doses: 300 mg/kg) as previously described⁴⁹. For the induction of cholestatic liver fibrosis mice underwent ligation of the common bile duct²⁷. Briefly, after abdominal incision, the common bile duct was ligated distally. For additional models of cholestatic liver fibrosis mice were either fed a 0.1% 3,5-diethoxycarbonyl-1,4-dihydro-collidin (DDC)-containing diet for 4 weeks or LratCre mice were crossed with Mdr2ko mice⁴⁸ in FVB/N background. ZsGreen, tdTomato and mTom/mGFP Cre reporter mice^{46,47} as well as Col-GFP reporter²² mice have been described elsewhere. As a model of fatty liver disease, liver fibrosis was induced by feeding mice a methionine-choline-deficient diet for nine weeks. 70% partial hepatectomy was performed as described⁵⁰. Briefly, after midline abdominal incision, the left lateral and the median liver lobes were mobilized, ligated and cut off⁵⁰. As models of liver injury with progenitor expansion, we employed above described DDC diet, and

methioninecholine-deficient diet combined with 0.15% ethionine supplementation in drinking water (MCDE diet)^{18,19}. All animal procedures were in accordance with guidelines by the National Institutes of Health, and approved by the Institutional Animal Care and Use Committee at Columbia University.

Primary cell isolations

Hepatic stellate cells were isolated from mice as described previously^{49,51}. Briefly, after cannulation of the inferior vena cava, the portal vein was cut, allowing retrograde step-wise perfusion with pronase (Sigma Aldrich, St. Louis, MO, United States) and collagenase (Roche, Germany) containing solutions, and subsequent 9.7% Nycodenz gradient centrifugation. Purity was assessed by vitamin A autofluorescence under a fluorescent microscope (Olympus 71IX). The entire population of non-parenchymal cells was isolated using pronase/collagenase perfusion and a 16.95% Nycodenz gradient. Murine hepatocytes were isolated by collagenase perfusion and low-density centrifugation with Percoll⁵². F4/80-positive hepatic macrophages were isolated after collagenase/pronase perfusion, followed by a 16.95% Nycodenz gradient and subsequent positive selection of F4/80-positive cells by magnetic-activated cell sorting (MACS) using biotinylated F4/80 antibody (clone: BM8, eBioscience, San Diego, CA, USA) and anti-biotin MACS beads (Miltenyi Biotec, Auburn, CA, USA)⁵³. Based on the specific marking of bile ducts by hGFAPCre, cholangiocytes were isolated by flow cytometry from hGFAPCre mice expressing ZsGreen Cre reporter after pronase/collagenase perfusion of mouse livers. Cholangiocyte identity was confirmed by western blot for cytokeratin 19. Liver sinusoidal endothelial cells were isolated by collagenase perfusion followed by MACS using anti-CD146 MACS beads (Miltenyi Biotec) and subsequent FACS to exclude HSCs in the isolate⁵⁴.

Analysis of vitamin A content and Col-GFP expression

Vitamin A fluorescence was analyzed by flow cytometry in isolated HSCs or non-parenchymal liver cells using 405-407 nm lasers for excitation and a 450/50 nm bandpass filter for detection. To determine vitamin A expression of activated HSCs, Col-GFP- and tdTomato-double positive cells were gated. Vitamin A-negative cells expressing Col-GFP were used as negative controls to set the threshold for positive signals for Vitamin A. GFP expression was analyzed using 488 nm lasers a 530/30 nm bandpass filter for detection. Non-parenchymal liver cell isolations from untreated Col-GFP-positive, LratCre-positive and tdTomato-positive mice were used to set the threshold for positive Col-GFP signals. TdTomato expression was analyzed using 488 nm lasers a 582/15 nm bandpass filter for detection. 4-6 independent cell isolates were analyzed for each model, using a minimum for 100,000 events for data evaluation. Flow-cytometric data was analyzed by FlowJo software.

Bone marrow transplantation

Bone marrow transplantation (BMT) was performed as described previously²⁷. Briefly, wild-type mice were macrophage-depleted by injection of liposomal clodronate, followed by lethal irradiation with 2×6 Gy and intravenous injection of 10×10^6 bone marrow cells from LratCre-positive, mTom/mGFP mice. Successful BMT was confirmed by the presence of mTom-positive cells in spleen and mTom-positive macrophages in the liver.

Immunohistochemical staining and microscopy

Immunohistochemistry was performed on frozen liver sections. Mouse livers were perfused with 4% paraformaldehyde and embedded. Frozen tissue blocks were cut to yield 5 μ m sections for immunohistochemical staining⁴⁹ using primary antibodies against desmin (1:300, rabbit, Lab Vision Cat.No RB-9014-P, Thermo Fisher Scientific, Fremont, CA, USA), α SMA (1:500, mouse, FITC-conjugated, Sigma-Aldrich F3777), Cytokeratin (1:250, rabbit, DAKO Z0622), F4/80 (1:250, rat, AbD serotec MCA497A64), CD31 (1:500, rat, Pharmingen 553369), PDGFR β (1:50, rabbit, Cell Signaling 3169) and HNF4 α (1:100, goat, Santa Cruz Biotechnology SC-6556), and matching secondary anti-rabbit (1:500, donkey, A21207), anti-rat (1:500, chicken, A21472), anti-FITC (1:1000, rabbit, A11090) and anti-goat (1:500, chicken, A21468) with various fluorescent conjugates (all Invitrogen). Confocal microscopy was performed on a Nikon A1 confocal laser microscope (Nikon Instruments, Melville, NY, USA) using a 20 \times lens or 40 \times and 60 \times oil immersion lenses. For some pictures and for quantification, 4-6 sections were merged. For macroscopic imaging, livers were visualized under a Leica MZ 16F fluorescent dissecting microscope.

Immunoblotting

Immunoblotting for Lrat, desmin or cytokeratin was performed on isolated primary hepatic cell populations using a mouse anti-Lrat antibody (dilution 1:5000)⁵⁵, desmin (Lab Vision, 1:2000) and cytokeratin 19 (rat, Troma-III, 1:1000, Developmental Studies Hybridoma Bank, University of Iowa). Briefly, cell or liver lysates were electrophoresed on 10% acrylamide SDS gels and transferred to nitrocellulose membrane. Loading was confirmed by Ponceau S staining. Blots were blocked in 5% nonfat dry milk, followed by overnight incubation at 4 degree Celsius with primary antibody, one hour incubation with horse-radish peroxidase-conjugated secondary antibody, and detection by luminescence (SuperSignal, ThermoScientific). Specificity of the Lrat antibody was determined using liver extracts from wild-type and Lrat knockout mice (Supplementary Fig. S10). Blots were reprobed with actin antibody (1:5000, MP Biomedicals) to confirm equal loading. Full-length images of all immunoblots are shown in Supplementary Fig. S10.

Quantification of positively stained cells

HNF4 α -positive hepatocytes were quantified in merged 20 \times pictures representing 70-100 random 20 \times fields per mouse. Three to four mice per treatment group were analyzed. To determine Col-GFP-positive cells or α SMA-positive cells originating from HSCs at least 50 random 40 \times pictures were analyzed per mouse. Experiments were performed in three to five animals per treatment group. Quantification of HNF4 α -positive, α SMA-positive cells and Col-GFP-positive cells and determination of co-localization with fluorescent Cre reporters were performed using ImageJ software.

Statistical evaluation

Statistical analysis was performed using Prism (GraphPad, San Diego, CA). Differences between two groups were calculated by Student's t-test. Significance of differences between multiple groups was determined by one-way ANOVA, followed by Dunnett's post-hoc test. All data are expressed as means \pm standard deviation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This study was supported by NIH grants U54CA163111 (Sub #5298) and 5R01DK76920 and 5R01DK075830 (to RFS). Ingmar Mederacke was supported by a postdoctoral fellowship from the American Liver Foundation and a fellowship from the German Research Foundation (ME 3723/1-1). Peter Huebener was supported by a fellowship from the German Research Foundation (Hu 1953/1-1). Dianne H. Dapito was supported by 1F31DK091980. We would like to thank Timothy Wang and Daniel Worthley, Columbia University, for help with HSC ablation experiments. We would like to thank David A. Brenner (University of California, San Diego) for kindly providing the transgenic Col1a1-GFP mouse line, and Krzysztof Palczewski (Case Western Reserve University) for providing Lrat antibody.

References

1. Mehal WZ, Iredale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. *Nat Med*. 2011; 17:552–553. [PubMed: 21546973]
2. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. *J Pathol*. 2003; 200:500–503. [PubMed: 12845617]
3. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med*. 2012; 18:1028–1040. [PubMed: 22772564]
4. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest*. 2005; 115:209–218. [PubMed: 15690074]
5. Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. *Hepatology*. 2010; 51:1438–1444. [PubMed: 20209607]
6. Iwaisako K, Brenner DA, Kisseleva T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. *J Gastroenterol Hepatol*. 2012; 27(Suppl 2):65–68. [PubMed: 22320919]
7. Perepelyuk M, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. *Am J Physiol Gastrointest Liver Physiol*. 2013; 304:G605–614. [PubMed: 23328207]
8. Kisseleva T, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. *J Hepatol*. 2006; 45:429–438. [PubMed: 16846660]
9. Friedman SL. Mechanisms of hepatic fibrogenesis. *Gastroenterology*. 2008; 134:1655–1669. [PubMed: 18471545]
10. De Minicis S, et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. *Gastroenterology*. 2007; 132:1937–1946. [PubMed: 17484886]
11. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. *Proc Natl Acad Sci U S A*. 1985; 82:8681–8685. [PubMed: 3909149]
12. Kisseleva T, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. *Proc Natl Acad Sci U S A*. 2012; 109:9448–9453. [PubMed: 22566629]
13. Scholten D, et al. Genetic labeling does not detect epithelial-to mesenchymal transition of cholangiocytes in liver fibrosis in mice. *Gastroenterology*. 2010; 139:987–998. [PubMed: 20546735]
14. Taura K, et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. *Hepatology*. 2010; 51:1027–1036. [PubMed: 20052656]
15. Chu AS, et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. *Hepatology*. 2011; 53:1685–1695. [PubMed: 21520179]
16. Li Y, Wang J, Asahina K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. *Proc Natl Acad Sci U S A*. 2013; 110:2324–2329. [PubMed: 23345421]
17. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. *Physiol Rev*. 2008; 88:125–172. [PubMed: 18195085]

18. Yang L, et al. Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. *Stem Cells*. 2008; 26:2104–2113. [PubMed: 18511600]
19. Michelotti GA, et al. Smoothed is a master regulator of adult liver repair. *J Clin Invest*. 2013; 123:2380–94. [PubMed: 23563311]
20. Blaner WS, et al. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. *Biochim Biophys Acta*. 2009; 1791:467–473. [PubMed: 19071229]
21. Nagatsuma K, et al. Lecithin: retinol acyltransferase protein is distributed in both hepatic stellate cells and endothelial cells of normal rodent and human liver. *Liver Int*. 2009; 29:47–54. [PubMed: 18544127]
22. Yata Y, et al. DNase I-hypersensitive sites enhance alpha1(I) collagen gene expression in hepatic stellate cells. *Hepatology*. 2003; 37:267–276. [PubMed: 12540776]
23. Buch T, et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. *Nat Methods*. 2005; 2:419–426. [PubMed: 15908920]
24. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell*. 2011; 21:193–215. [PubMed: 21839917]
25. Asahina K, Zhou B, Pu WT, Tsukamoto H. Septum transversum- derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. *Hepatology*. 2011; 53:983–995. [PubMed: 21294146]
26. Russo FP, et al. The bone marrow functionally contributes to liver fibrosis. *Gastroenterology*. 2006; 130:1807–1821. [PubMed: 16697743]
27. Seki E, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med*. 2007; 13:1324–1332. [PubMed: 17952090]
28. Higashiyama R, et al. Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice. *Gastroenterology*. 2009; 137:1459–1466. e1451. [PubMed: 19596008]
29. Sancho-Bru P, et al. Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. *J Hepatol*. 2005; 43:272–282. [PubMed: 15964095]
30. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. *Sci Transl Med*. 2013; 5:167sr161.
31. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. *J Clin Invest*. 2013; 123:1887–1901. [PubMed: 23635787]
32. Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation? *J Hepatol* 56 Suppl. 2012; 1:S66–74.
33. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. *Semin Liver Dis*. 2007; 27:77–98. [PubMed: 17295178]
34. Espanol-Suner R, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. *Gastroenterology*. 2012; 143:1564–1575. e1567. [PubMed: 22922013]
35. Malato Y, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. *J Clin Invest*. 2011; 121:4850–4860. [PubMed: 22105172]
36. Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. *Science*. 2008; 322:1490–1494. [PubMed: 19056973]
37. Lujambio A, et al. Non-cell-autonomous tumor suppression by p53. *Cell*. 2013; 153:449–460. [PubMed: 23562644]
38. Hernandez-Gea V, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology*. 2012; 142:938–946. [PubMed: 22240484]
39. Humphreys BD, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. *Am J Pathol*. 2010; 176:85–97. [PubMed: 20008127]
40. Hung C, et al. Role of Lung Pericytes and Resident Fibroblasts in the Pathogenesis of Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2013; 188:820–30. [PubMed: 23924232]
41. Goritz C, et al. A pericyte origin of spinal cord scar tissue. *Science*. 2011; 333:238–242. [PubMed: 21737741]
42. Lebleu VS, et al. Origin and function of myofibroblasts in kidney fibrosis. *Nat Med*. 2013

43. Rock JR, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. *Proc Natl Acad Sci U S A*. 2011; 108:E1475–1483. [PubMed: 22123957]
44. Zhuo L, et al. hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. *Genesis*. 2001; 31:85–94. [PubMed: 11668683]
45. Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. *Nat Neurosci*. 2004; 7:1233–1241. [PubMed: 15494728]
46. Madisen L, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat Neurosci*. 2010; 13:133–140. [PubMed: 20023653]
47. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. *Genesis*. 2007; 45:593–605. [PubMed: 17868096]
48. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. *Mdr2* (*Abcb4*)^{-/-} mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. *J Hepatol*. 2005; 43:1045–1054. [PubMed: 16223543]
49. Troeger JS, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. *Gastroenterology*. 2012; 143:1073–1083. e1022. [PubMed: 22750464]
50. Mitchell C, Willenbring H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. *Nat Protoc*. 2008; 3:1167–1170. [PubMed: 18600221]
51. Dapito DH, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. *Cancer Cell*. 2012; 21:504–516. [PubMed: 22516259]
52. Siegmund SV, et al. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. *J Biol Chem*. 2006; 281:10431–10438. [PubMed: 16418162]
53. Pradere JP, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells. *Hepatology*. 2013; 58:1461–73. [PubMed: 23553591]
54. Kluwe J, et al. Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis. *Gut*. 2011; 60:1260–1268. [PubMed: 21278145]
55. Batten ML, et al. Lecithin-retinol acyltransferase is essential for accumulation of all-trans-retinyl esters in the eye and in the liver. *J Biol Chem*. 2004; 279:10422–10432. [PubMed: 14684738]




Figure 1. GFAPCre marks extra- and intrahepatic bile ducts but not HSCs

A. Macroscopic images demonstrate hGFAPCre-induced ZsGreen Cre reporter fluorescence in extrahepatic bile ducts, the brain and brain sections (n=1). **B-C.** HSCs were isolated from hGFAPCre mice expressing ZsGreen (n=2), and either plated (B), or analyzed by flow-cytometry (C). RlatCre mice served as positive control (n=3). **D.** HSCs were isolated from hGFAPCre mice expressing mTom/mGFP Cre reporter, and plated (n=1). **E.** Sections from untreated (n=1), bile duct-ligated (n=1) and CCl₄-treated livers (n=2) were stained for desmin, showing no co-localization of ZsGreen and HSC marker desmin by confocal microscopy. **F.** Representative western blot (out of n=3) showing cytoke­ratin 19 expression but no desmin expression in FACS-sorted hGFAP-Cre labeled ZsGreen positive cells. **G.** hGFAPCre mice undergoing either BDL (n=1) or CCl₄ treatment (n=1) show no overlap between tdTomato Cre reporter and Col-GFP reporter, thus excluding a contribution of hGFAPCre-labeled cells to ECM-producing myofibroblasts. **H.** Cytokeratin staining of bile duct-ligated hGFAPCre mice shows almost complete overlap of cytoke­ratin, marking the bile duct proliferates, and hGFAPCre-induced ZsGreen expression (n=1). **I.** Sections from untreated mice expressing Cre under the murine Gfap promoter and mTom/mGFP Cre reporter show no GFP expression in the liver. Brain served as positive control (Inlet). Scale bars, 4 mm (A, left panel), 2 mm (A, upper middle and right panel) 200 μm (A, lower middle and right panel) and 50 μm (B, D, E, G-I).




Figure 2. LratCre efficiently labels hepatic stellate cells

A. Lrat expression was determined by western blot in pure and never-plated primary murine HSCs (n=8), hepatocytes (n=2), Kupffer cells (n=2), endothelial cells (n=2), and cholangiocytes (n=2). **B-C.** HSCs were isolated from LratCre negative (n=2) and LratCre-positive mice (n=3) expressing ZsGreen Cre reporter and either plated for 24h (B), or analyzed by flow cytometry (C), using vitamin A (“VitA”, determined in the violet FACS channel) fluorescence as HSC marker in both approaches. **D.** Co-localization of LratCre-induced ZsGreen expression and desmin was determined in untreated livers using confocal microscopy (n=4) **E.** Co-localization of LratCre-induced ZsGreen expression and CD31 (marking endothelial cells), F4/80 (marking macrophages), HNF4α (marking hepatocytes) and cytokeratin (marking cholangiocytes) was determined by confocal microscopy in untreated and CCl₄-treated mice. Scale bars 100 μm (B, D-E).




Figure 3. Hepatic stellate cells are the principal source of myofibroblasts in CCl₄-induced liver fibrosis

A. Representative fluorescent images of whole livers from untreated and CCl₄-treated (n=3) show LratCre-labeled ZsGreen-positive macroscopic fibrotic septa in CCl₄-treated liver. **B.** Frozen liver sections from CCl₄-treated LratCre-positive mice were stained with desmin (upper panel) or αSMA (middle panel) to demonstrate co-localization of HSC marker desmin or αSMA and LratCre-induced ZsGreen by confocal microscopy. Confocal microscopy was employed to show co-localization of Col-GFP reporter, marking activated myofibroblasts, and LratCre-induced tdTomato expression (lower panel). Quantification of αSMA-expressing cells that are derived from LratCre-labeled ZsGreen-positive HSCs in fibrosis induced by 9x CCl₄ (n=4, upper graph) or Col-GFP-expressing cells that are derived from LratCre-labeled tdTomato-positive HSCs in fibrosis induced by 9x CCl₄ treatment (n=4, lower graph). **C.** Co-localization of αSMA with tdTomato and Col-GFP in 9x CCl₄-induced liver fibrosis was determined by confocal microscopy employing far-red secondary antibody for αSMA detection. **D-E.** LratCre mice, expressing Cre-inducible diphtheria toxin receptor (iDTR) received either vehicle (n=4) or diphtheria toxin (DT, n=4) during CCl₄-induced liver fibrosis induction. Expression of αSMA and desmin was determined by immunohistochemistry and quantified (D), expression of fibrogenic genes was determined by

qPCR (E). Scale bars 1 mm (A), 100 μm (B-C), 200 μm (D). Data are shown as means \pm SD.
* $p < 0.05$; ** $p < 0.01$ (determined by Student t-test).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Hepatic stellate cells are the principal source of myofibroblasts in cholestatic liver fibrosis

A-C. Liver sections of 14 day bile duct-ligated (BDL) mice (A, ZsGreen n=3, tdTom/ColGFP n=4), 9 week old *Mdr2*^{ko} mice (B, ZsGreen n=4, tdTom/ColGFP n=5), or 0.1% DDC-diet treated mice (C, ZsGreen n=4, tdTom/ColGFP n=3) were stained with desmin to demonstrate co-localization of HSC marker desmin and LratCre-induced ZsGreen by confocal microscopy (upper panel). Confocal microscopy was employed to show co-localization of Col-GFP reporter, marking activated myofibroblasts, and LratCre-induced tdTomato expression (lower panel). **D.** Flow-cytometric images from two week BDL mice (upper panel) and nine-week old *Mdr2*^{ko} (lower panel) mice, co-expressing LratCre, tdTomato and Col-GFP. Images next to FACS plots show sorted cells freshly after plating. **E.** Quantification of Col-GFP-expressing cells, derived from LratCre-labeled tdTomato-positive HSCs, was performed in liver sections (14d BDL: n=4; *Mdr2*^{ko} n=5; 0.1% DDC diet: n=3) or in non-parenchymal cell fractions using flow cytometry (14d BDL: n=4, *Mdr2*^{ko} n=6). **F.** Images demonstrating small and large bile ducts surrounded by Col-GFP-positive and LratCre-negative portal fibroblasts. **G.** qPCR of FACS-sorted unsorted LratCre-labeled tdTomato-positive and Col-GFP-positive cells (HSC, n=5 isolates) and tdTomato-negative and Col-GFP-positive cells (portal fibroblast-like cells, PFLC, n=5 isolates). **H.**

Representative images of HSCs and PFLC show morphologically distinct cell populations. Scale bars 100 μm (A-C), 10 μm (D), 100 μm (F), 50 μm (H). Data are shown as means \pm SD. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ (determined by Student t-test).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. HSCs do not contribute to the generation of newly formed hepatocytes

A-G. Determination of possible co-localization of hepatocyte marker HNF4 α and LratCre-induced ZsGreen was performed by confocal microscopy in untreated mice (n=4) (A), mice receiving MCDE diet for three weeks followed by three weeks recovery on regular chow (n=4) (B), mice receiving DDC diet for four weeks followed by three weeks recovery (n=3) (C), mice undergoing BDL for two weeks (n=3) (D), 9-15 week old Mdr2^{ko} mice (n=3) (E), or two weeks after partial hepatectomy (n=3) (F). The number of HNF4 α -expressing hepatocytes, positive for ZsGreen, was quantified from confocal microscope images (G). **H-I.** Representative images of primary hepatocytes, isolated from control mice (n=3) and mice that received MCDE diet for three weeks (n=4), followed by three weeks recovery (H). Positive control (“+ ctrl”) from AAV8-TBG-Cre infected mice showing ZsGreen-positive hepatocytes (n=1) (H, upper right insert). The rare ZsGreen-positive small-size cells were identified as HSCs by their characteristic fluorescent retinoid-containing lipid droplets (H, lower right inserts). ZsGreen-positive hepatocytes were quantified (I). Scale bars, 100 μ m. Data are shown as means \pm SD. n.s., non-significant (one-way ANOVA).




Figure 6. LratCre-labeled HSCs are not bone marrow-derived

A-C. Bone marrow from mice expressing LratCre and mTom/mGFP-Cre reporter was transplanted into lethally irradiated wild-type recipients. Untreated (n=2), 20× CCl₄ (n=1) and 3 weeks BDL (n=1) treated mice were sacrificed 5-6 months after BMT, and showed no LratCre-induced mGFP expression, thus excluding a contribution of the BM to generation of LratCre-expressing HSCs. In contrast, LratCre-positive mice expressing mTom/mGFP, serving as positive control, showed abundant mGFP signal (A). Successful BMT was confirmed by the presence mTom-positive cells in spleen (see inserts) and demonstration of F4/80-positive mGFP-expressing liver macrophages (B). HSCs isolated from BM-transplanted mice (n=1) showed no mGFP signal or by flow-cytometric analysis, whereas controls showed abundant mGFP signal (n=4) (C). Scale bars 100 μm.